Human placental lactogen

Revision as of 16:05, 9 August 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
chorionic somatomammotropin hormone 1 (placental lactogen)
Identifiers
SymbolCSH1
Entrez1442
HUGO2440
OMIM150200
RefSeqNM_001317
UniProtQ6PF11
Other data
LocusChr. 17 q22-q24
chorionic somatomammotropin hormone 2
Identifiers
SymbolCSH2
Entrez1443
HUGO2441
OMIM118820
RefSeqNM_020991
UniProtP01243
Other data
LocusChr. 17 q22-q24

WikiDoc Resources for Human placental lactogen

Articles

Most recent articles on Human placental lactogen

Most cited articles on Human placental lactogen

Review articles on Human placental lactogen

Articles on Human placental lactogen in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Human placental lactogen

Images of Human placental lactogen

Photos of Human placental lactogen

Podcasts & MP3s on Human placental lactogen

Videos on Human placental lactogen

Evidence Based Medicine

Cochrane Collaboration on Human placental lactogen

Bandolier on Human placental lactogen

TRIP on Human placental lactogen

Clinical Trials

Ongoing Trials on Human placental lactogen at Clinical Trials.gov

Trial results on Human placental lactogen

Clinical Trials on Human placental lactogen at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Human placental lactogen

NICE Guidance on Human placental lactogen

NHS PRODIGY Guidance

FDA on Human placental lactogen

CDC on Human placental lactogen

Books

Books on Human placental lactogen

News

Human placental lactogen in the news

Be alerted to news on Human placental lactogen

News trends on Human placental lactogen

Commentary

Blogs on Human placental lactogen

Definitions

Definitions of Human placental lactogen

Patient Resources / Community

Patient resources on Human placental lactogen

Discussion groups on Human placental lactogen

Patient Handouts on Human placental lactogen

Directions to Hospitals Treating Human placental lactogen

Risk calculators and risk factors for Human placental lactogen

Healthcare Provider Resources

Symptoms of Human placental lactogen

Causes & Risk Factors for Human placental lactogen

Diagnostic studies for Human placental lactogen

Treatment of Human placental lactogen

Continuing Medical Education (CME)

CME Programs on Human placental lactogen

International

Human placental lactogen en Espanol

Human placental lactogen en Francais

Business

Human placental lactogen in the Marketplace

Patents on Human placental lactogen

Experimental / Informatics

List of terms related to Human placental lactogen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753



Human placental lactogen (HPL), also called human chorionic somatomammotropin, is a polypeptide placental hormone. Its structure and function is similar to that of human growth hormone. It modifies the metabolic state of the mother during pregnancy to facilitate the energy supply of the fetus. HPL is an anti-insulin.

Structure

HPL consists of 190 amino acids that are linked by two disulfite bonds and is secreted by the syncytiotrophoblast during pregnancy. Its molecular weight is 22,125. Like human growth hormone HPL is encoded by genes on chromosome 17q22-24. Its biologic half-life is 15 minutes.

Levels

HPL is only present during pregnancy with maternal serum levels rising in relation to the growth of the fetus and placenta. Maximum levels are reached near term, typically to 5–7 mg/ml. Higher levels are noted in patients with multiple gestation. Little HPL enters the fetal circulation.

Function

In a bioassay HPL mimics the action of prolactin, yet it is unclear if HPL has any role in human lactation.

HPL affects the metabolic system of the maternal organism. HPL increases production of insulin and IGF-1 and increases insulin resistance and carbohydrate intolerance. Chronic hypoglycemia leads to a rise in HPL. HPL induces lipolysis with the release of free fatty acids, increase in insulin secretion and insulin resistance. With fasting and release of HPL, free fatty acids become available for the maternal organism as fuel, so that relatively more glucose can be utilized by the fetus. Also, ketones formed from free fatty acids can cross the placenta and be used by the fetus. These events support energy supply to the fetus in states of starvation.

Clinical measurement of HPL

While HPL has been used as an indicator of fetal well-being and growth, other fetal monitoring methods have been found to be more reliable. Also, normal pregnancies have been reported with undetectable maternal levels of HPL.

References

  • Speroff L, Glass RH, Kase NG. Clinical Gynecologic Endocrinology and Infertility. Sixth edition. Lippincott Williams & Wilkins, Baltimore, MD 1999. ISNB 0-683-30379-1.

External links

Template:WikiDoc Sources

de:Humanes Plazentalaktogen